Telomere biology in hematopoiesis and stem cell transplantation

Blood Reviews

Volumn 25, Issue 6, 2011, Pages 261-269

  Gadalla, Shahinaz M ^a   Savage, Sharon A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bone marrow failure disorders; Dyskeratosis congenita; Hematopoietic stem cell transplant; Myelodysplastic syndrome; Pluripotent stem cells; Telomeres

Indexed keywords

ALEMTUZUMAB; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; FLUDARABINE; MULTIPROTEIN COMPLEX;

APLASTIC ANEMIA; ARTICLE; BONE MARROW DISEASE; CELL AGING; CELL DIVISION; CELL PROLIFERATION; CHROMOSOME; DONOR; DYSKERATOSIS CONGENITA; GRAFT RECIPIENT; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; NUCLEOTIDE REPEAT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; TELOMERE; UMBILICAL CORD BLOOD;

ANIMALS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; STEM CELL TRANSPLANTATION; TELOMERE; TELOMERE SHORTENING;

EID: 80055020926     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2011.06.004     Document Type: Article

References (157)

1. Olovnikov A.M. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J. Theor. Biol. 1973, 41:181-190.
2. Greider C.W., Blackburn E.H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985, 43:405-413.
3. Blackburn E.H. Structure and function of telomeres. Nature 1991, 350:569-573.
4. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
5. Nalapareddy K., Jiang H., Guachalla Gutierrez L.M., Rudolph K.L. Determining the influence of telomere dysfunction and DNA damage on stem and progenitor cell aging: what markers can we use?. Exp. Gerontol. 2008, 43:998-1004.
6. Harley C.B., Vaziri H., Counter C.M., Allsopp R.C. The telomere hypothesis of cellular aging. Exp. Gerontol. 1992, 27:375-382.
7. Takubo K., Aida J., Izumiyama-Shimomura N., Ishikawa N., Sawabe M., Kurabayashi R., et al. Changes of telomere length with aging. Geriatr. Gerontol. Int. 2010, 10(Suppl 1):S197-S206.
8. Nordfjall K., Svenson U., Norrback K.F., Adolfsson R., Lenner P., Roos G. The individual blood cell telomere attrition rate is telomere length dependent. PLoS Genet. 2009, 5:e1000375.
9. Aviv A., Chen W., Gardner J.P., Kimura M., Brimacombe M., Cao X., et al. Leukocyte telomere dynamics: longitudinal findings among young adults in the Bogalusa Heart Study. Am. J. Epidemiol. 2009, 169:323-329.
10. Harle-Bachor C., Boukamp P. Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:6476-6481.
11. Hiyama K., Hirai Y., Kyoizumi S., Akiyama M., Hiyama E., Piatyszek M.A., et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 1995, 155:3711-3715.
12. Cong Y.S., Wright W.E., Shay J.W. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 2002, 66:407-425. table.
13. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer 1997, 33:787-791.
14. Cesare A.J., Reddel R.R. Alternative lengthening of telomeres: models, mechanisms and implications. Nat. Rev. Genet. 2010, 11:319-330.
15. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005, 19:2100-2110.
16. Palm W., LT de How shelterin protects mammalian telomeres. Annu. Rev. Genet. 2008, 42:301-334.
17. Martens U.M., Zijlmans J.M., Poon S.S., Dragowska W., Yui J., Chavez E.A., et al. Short telomeres on human chromosome 17p. Nat. Genet. 1998, 18:76-80.
18. Moller P., Mayer S., Mattfeldt T., Muller K., Wiegand P., Bruderlein S. Sex-related differences in length and erosion dynamics of human telomeres favor females. Aging (Albany. NY) 2009, 1:733-739.
19. Butler M.G., Tilburt J., DeVries A., Muralidhar B., Aue G., Hedges L., et al. Comparison of chromosome telomere integrity in multiple tissues from subjects at different ages. Cancer Genet. Cytogenet. 1998, 105:138-144.
20. Mondello C., Petropoulou C., Monti D., Gonos E.S., Franceschi C., Nuzzo F. Telomere length in fibroblasts and blood cells from healthy centenarians. Exp. Cell Res. 1999, 248:234-242.
21. Friedrich U., Griese E., Schwab M., Fritz P., Thon K., Klotz U. Telomere length in different tissues of elderly patients. Mech. Ageing Dev. 2000, 119:89-99.
22. Nakamura K., Izumiyama-Shimomura N., Sawabe M., Arai T., Aoyagi Y., Fujiwara M., et al. Comparative analysis of telomere lengths and erosion with age in human epidermis and lingual epithelium. J. Invest. Dermatol. 2002, 119:1014-1019.
23. Takubo K., Izumiyama-Shimomura N., Honma N., Sawabe M., Arai T., Kato M., et al. Telomere lengths are characteristic in each human individual. Exp. Gerontol. 2002, 37:523-531.
24. Thibeault S.L., Glade R.S., Li W. Comparison of telomere length of vocal folds with different tissues: a physiological measurement of vocal senescence. J. Voice 2006, 20:165-170.
25. Gadalla S.M., Cawthon R., Giri N., Alter B.P., Savage S.A. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging (Albany. NY) 2010, 2:867-874.
26. Baird D.M. New developments in telomere length analysis. Exp. Gerontol. 2005, 40:363-368.
27. Lin K.W., Yan J. The telomere length dynamic and methods of its assessment. J. Cell. Mol. Med. 2005, 9:977-989.
28. Lansdorp P.M. Telomere length and proliferation potential of hematopoietic stem cells. J. Cell Sci. 1995, 108(Pt 1):1-6.
29. Hills M., Lucke K., Chavez E.A., Eaves C.J., Lansdorp P.M. Probing the mitotic history and developmental stage of hematopoietic cells using single telomere length analysis (STELA). Blood 2009, 113:5765-5775.
30. Zeichner S.L., Palumbo P., Feng Y., Xiao X., Gee D., Sleasman J., et al. Rapid telomere shortening in children. Blood 1999, 93:2824-2830.
31. Rufer N., Brummendorf T.H., Kolvraa S., Bischoff C., Christensen K., Wadsworth L., et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J. Exp. Med. 1999, 190:157-167.
32. Martens U.M., Brass V., Sedlacek L., Pantic M., Exner C., Guo Y., et al. Telomere maintenance in human B lymphocytes. Br. J. Haematol. 2002, 119:810-818.
33. Son N.H., Murray S., Yanovski J., Hodes R.J., Weng N. Lineage-specific telomere shortening and unaltered capacity for telomerase expression in human T and B lymphocytes with age. J. Immunol. 2000, 165:1191-1196.
34. Rufer N., Dragowska W., Thornbury G., Roosnek E., Lansdorp P.M. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat. Biotechnol. 1998, 16:743-747.
35. Kimura M., Gazitt Y., Cao X., Zhao X., Lansdorp P.M., Aviv A. Synchrony of telomere length among hematopoietic cells. Exp. Hematol. 2010.
36. Heiss N.S., Knight S.W., Vulliamy T.J., Klauck S.M., Wiemann S., Mason P.J., et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat. Genet. 1998, 19:32-38.
37. Mitchell J.R., Wood E., Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999, 402:551-555.
38. Savage S.A., Alter B.P. Dyskeratosis congenita. Hematol. Oncol. Clin. North Am. 2009, 23:215-231.
39. Al Rahawan M.M., Giri N., Alter B.P. Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita. Int. J. Hematol. 2006, 83:275-276.
40. de la Fuente J., Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr. Transplant. 2007, 11:584-594.
41. Armanios M. Syndromes of telomere shortening. Annu. Rev. Genomics Hum. Genet. 2009.
42. Alter B.P., Giri N., Savage S.A., Rosenberg P.S. Cancer in dyskeratosis congenita. Blood 2009.
43. Zhong F., Savage S.A., Shkreli M., Giri N., Jessop L., Myers T., et al. Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. Genes Dev. 2011, 25:11-16.
44. Alter B.P., Baerlocher G.M., Savage S.A., Chanock S.J., Weksler B.B., Willner J.P., et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 2007, 110:1439-1447.
45. Du H.Y., Pumbo E., Ivanovich J., An P., Maziarz R.T., Reiss U.M., et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 2009, 113:309-316.
46. Savage S.A., Bertuch A.A. The genetics and clinical manifestations of telomere biology disorders. Genet. Med. 2010, 12:753-764.
47. Savage S.A., Alter B.P. The role of telomere biology in bone marrow failure and other disorders. Mech. Ageing Dev. 2008, 129:35-47.
48. Calado R.T., Young N.S. Telomere maintenance and human bone marrow failure. Blood 2008, 111:4446-4455.
49. Ball S.E., Gibson F.M., Rizzo S., Tooze J.A., Marsh J.C., Gordon-Smith E.C. Progressive telomere shortening in aplastic anemia. Blood 1998, 91:3582-3592.
50. Scheinberg P., Cooper J.N., Sloand E.M., Wu C.O., Calado R.T., Young N.S. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA 2010, 304:1358-1364.
51. Komrokji R.S., Zhang L., Bennett J.M. Myelodysplastic syndromes classification and risk stratification. Hematol. Oncol. Clin. North Am. 2010, 24:443-457.
52. Lange K., Holm L., Vang N.K., Hahn A., Hofmann W., Kreipe H., et al. Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 2010, 49:260-269.
53. Ohyashiki K., Iwama H., Yahata N., Tauchi T., Kawakubo K., Shimamoto T., et al. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leuk. Lymphoma 2001, 42:291-299.
54. Kirwan M., Vulliamy T., Marrone A., Walne A.J., Beswick R., Hillmen P., et al. Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum. Mutat. 2009, 30:1567-1573.
55. Calado R.T., Regal J.A., Hills M., Yewdell W.T., Dalmazzo L.F., Zago M.A., et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:1187-1192.
56. Ohyashiki J.H., Iwama H., Yahata N., Ando K., Hayashi S., Shay J.W., et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin. Cancer Res. 1999, 5:1155-1160.
57. Gurkan E., Tanriverdi K., Baslamisli F. Telomerase activity in myelodysplastic syndromes. Leuk. Res. 2005, 29:1131-1139.
58. Boultwood J., Fidler C., Kusec R., Rack K., Elliott P.J., Atoyebi O., et al. Telomere length in myelodysplastic syndromes. Am. J. Hematol. 1997, 56:266-271.
59. Deville L., Hillion J., Lanotte M., Rousselot P., Segal-Bendirdjian E. Diagnostics, prognostic and therapeutic exploitation of telomeres and telomerase in leukemias. Curr. Pharm. Biotechnol. 2006, 7:171-183.
60. Yamada O. Telomeres and telomerase in human hematologic neoplasia. Int. J. Hematol. 1996, 64:87-99.
61. Ohyashiki J.H., Sashida G., Tauchi T., Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002, 21:680-687.
62. Engelhardt M., Mackenzie K., Drullinsky P., Silver R.T., Moore M.A. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res. 2000, 60:610-617.
63. Capraro V., Zane L., Poncet D., Perol D., Galia P., Preudhomme C., et al. Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Exp. Hematol. 2010.
64. Brummendorf T.H., Rufer N., Holyoake T.L., Maciejewski J., Barnett M.J., Eaves C.J., et al. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. Ann. N. Y. Acad. Sci. 2001, 938:293-303.
65. Drummond M.W., Hoare S.F., Monaghan A., Graham S.M., Alcorn M.J., Keith W.N., et al. Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia 2005, 19:381-389.
66. Wang Y., Fang M., Sun X., Sun J. Telomerase activity and telomere length in acute leukemia: correlations with disease progression, subtypes and overall survival. Int. J. Lab. Hematol. 2010, 32:230-238. Epub 2009 Jul 15.
67. Kubuki Y., Suzuki M., Sasaki H., Toyama T., Yamashita K., Maeda K., et al. Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk. Lymphoma 2005, 46:393-399.
68. Keller G., Brassat U., Braig M., Heim D., Wege H., Brummendorf T.H. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy. Hematol. Oncol. 2009, 27:123-129.
69. Kleideiter E., Bangerter U., Schwab M., Boukamp P., Koscielniak E., Klotz U., et al. Telomeres and telomerase in paediatric patients with T-cell acute lymphoblastic leukaemia (T-ALL). Leukemia 2005, 19:296-298.
70. Boultwood J., Fidler C., Shepherd P., Watkins F., Snowball J., Haynes S., et al. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. Am. J. Hematol. 1999, 61:5-9.
71. Boultwood J., Peniket A., Watkins F., Shepherd P., McGale P., Richards S., et al. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood 2000, 96:358-361.
72. Ohyashiki K., Ohyashiki J.H., Iwama H., Hayashi S., Shay J.W., Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 1997, 11:190-194.
73. Ohyashiki K., Iwama H., Tauchi T., Shimamoto T., Hayashi S., Ando K., et al. Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia. Leuk. Lymphoma 2000, 40:49-56.
74. Brummendorf T.H., Ersoz I., Hartmann U., Balabanov S., Wolke H., Paschka P., et al. Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia. Ann. N. Y. Acad. Sci. 2003, 996:26-38.
75. Yamada O., Kawauchi K., Akiyama M., Ozaki K., Motoji T., Adachi T., et al. Leukemic cells with increased telomerase activity exhibit resistance to imatinib. Leuk. Lymphoma 2008, 49:1168-1177.
76. Copelan E.A. Hematopoietic stem-cell transplantation. N. Engl. J. Med. 2006, 354:1813-1826.
77. Thornley I., Sutherland R., Wynn R., Nayar R., Sung L., Corpus G., et al. Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. Blood 2002, 99:2387-2396.
78. Novitzky N., Mohammed R. Alterations in the progenitor cell population follow recovery from myeloablative therapy and bone marrow transplantation. Exp. Hematol. 1997, 25:471-477.
79. Podesta M., Piaggio G., Frassoni F., Pitto A., Mordini N., Bregante S., et al. Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997, 19:1011-1017.
80. Brummendorf T.H., Balabanov S. Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. Leukemia 2006, 20:1706-1716.
81. Akiyama M., Asai O., Kuraishi Y., Urashima M., Hoshi Y., Sakamaki H., et al. Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2000, 25:441-447.
82. Lahav M., Uziel O., Kestenbaum M., Fraser A., Shapiro H., Radnay J., et al. Nonmyeloablative conditioning does not prevent telomere shortening after allogeneic stem cell transplantation. Transplantation 2005, 80:969-976.
83. Brummendorf T.H., Rufer N., Baerlocher G.M., Roosnek E., Lansdorp P.M. Limited telomere shortening in hematopoietic stem cells after transplantation. Ann. N. Y. Acad. Sci. 2001, 938:1-7.
84. Robertson J.D., Testa N.G., Russell N.H., Jackson G., Parker A.N., Milligan D.W., et al. Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant. 2001, 27:1283-1286.
85. Roelofs H., de Pauw E.S., Zwinderman A.H., Opdam S.M., Willemze R., Tanke H.J., et al. Homeostasis of telomere length rather than telomere shortening after allogeneic peripheral blood stem cell transplantation. Blood 2003, 101:358-362.
86. Champlin R.E., Schmitz N., Horowitz M.M., Chapuis B., Chopra R., Cornelissen J.J., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR histocompatibility and stem cell sources working committee and the European group for blood and marrow transplantation (EBMT). Blood 2000, 95:3702-3709.
87. Mahmoud H., Fahmy O., Kamel A., Kamel M., El-Haddad A., El-Kadi D. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 1999, 24:355-358.
88. Notaro R., Cimmino A., Tabarini D., Rotoli B., Luzzatto L. In vivo telomere dynamics of human hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:13782-13785.
89. Pipes B.L., Tsang T., Peng S.X., Fiederlein R., Graham M., Harris D.T. Telomere length changes after umbilical cord blood transplant. Transfusion 2006, 46:1038-1043.
90. de Pauw E.S., Verwoerd N.P., Duinkerken N., Willemze R., Raap A.K., Fibbe W.E., et al. Assessment of telomere length in hematopoietic interphase cells using in situ hybridization and digital fluorescence microscopy. Cytometry 1998, 32:163-169.
91. Friedrich U., Schwab M., Griese E.U., Fritz P., Klotz U. Telomeres in neonates: new insights in fetal hematopoiesis. Pediatr. Res. 2001, 49:252-256.
92. Ruella M., Rocci A., Ricca I., Carniti C., Bodoni C.L., Ladetto M., et al. Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. Bone Marrow Transplant. 2010, 45:505-512.
93. Allsopp R.C., Cheshier S., Weissman I.L. Telomerase activation and rejuvenation of telomere length in stimulated T cells derived from serially transplanted hematopoietic stem cells. J. Exp. Med. 2002, 196:1427-1433.
94. Allsopp R.C., Morin G.B., DePinho R., Harley C.B., Weissman I.L. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood 2003, 102:517-520.
95. Baerlocher G.M., Rovo A., Muller A., Matthey S., Stern M., Halter J., et al. Cellular senescence of white blood cells in very long-term survivors after allogeneic hematopoietic stem cell transplantation: the role of chronic graft-versus-host disease and female donor sex. Blood 2009, 114:219-222.
96. de Pauw E.S., Otto S.A., Wijnen J.T., Vossen J.M., van Weel M.H., Tanke H.J., et al. Long-term follow-up of recipients of allogeneic bone marrow grafts reveals no progressive telomere shortening and provides no evidence for haematopoietic stem cell exhaustion. Br. J. Haematol. 2002, 116:491-496.
97. Blasco M.A., Lee H.W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91:25-34.
98. Chang S. Modeling premature aging syndromes with the telomerase knockout mouse. Curr. Mol. Med. 2005, 5:153-158.
99. Ju Z., Jiang H., Jaworski M., Rathinam C., Gompf A., Klein C., et al. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat. Med. 2007, 13:742-747.
100. Song Z., Wang J., Guachalla L.M., Terszowski G., Rodewald H.R., Ju Z., et al. Alterations of the systemic environment are the primary cause of impaired B and T lymphopoiesis in telomere-dysfunctional mice. Blood 2010, 115:1481-1489.
101. Awaya N., Baerlocher G.M., Manley T.J., Sanders J.E., Mielcarek M., Torok-Storb B., et al. Telomere shortening in hematopoietic stem cell transplantation: a potential mechanism for late graft failure? Biol. Blood Marrow Transplant. 2002, 8:597-600.
102. Dietz A.C., Orchard P.J., Baker K.S., Giller R.H., Savage S.A., Alter B.P., et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant. 2011, 46:98-104.
103. Fogarty P.F., Yamaguchi H., Wiestner A., Baerlocher G.M., Sloand E., Zeng W.S., et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003, 362:1628-1630.
104. Kollman C., Howe C.W., Anasetti C., Antin J.H., Davies S.M., Filipovich A.H., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
105. Schultz K.R., Green G.J., Wensley D., Sargent M.A., Magee J.F., Spinelli J.J., et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1994, 84:3212-3220.
106. Dudek A.Z., Mahaseth H., DeFor T.E., Weisdorf D.J. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol. Blood Marrow Transplant. 2003, 9:657-666.
107. Davies S.M., Kollman C., Anasetti C., Antin J.H., Gajewski J., Casper J.T., et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000, 96:4096-4102.
108. Gross T.G., Steinbuch M., DeFor T., Shapiro R.S., McGlave P., Ramsay N.K., et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant. 1999, 23:251-258.
109. Koppelstaetter C., Schratzberger G., Perco P., Hofer J., Mark W., Ollinger R., et al. Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation. Aging Cell 2008, 7:491-497.
110. McGlynn L.M., Stevenson K., Lamb K., Zino S., Brown M., Prina A., et al. Cellular senescence in pretransplant renal biopsies predicts postoperative organ function. Aging Cell 2009, 8:45-51.
111. Koetz K., Bryl E., Spickschen K., O'Fallon W.M., Goronzy J.J., Weyand C.M. T cell homeostasis in patients with rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:9203-9208.
112. Honda M., Mengesha E., Albano S., Nichols W.S., Wallace D.J., Metzger A., et al. Telomere shortening and decreased replicative potential, contrasted by continued proliferation of telomerase-positive CD8+CD28(lo) T cells in patients with systemic lupus erythematosus. Clin. Immunol. 2001, 99:211-221.
113. O'Sullivan J.N., Bronner M.P., Brentnall T.A., Finley J.C., Shen W.T., Emerson S., et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat. Genet. 2002, 32:280-284.
114. Salpea K.D., Humphries S.E. Telomere length in atherosclerosis and diabetes. Atherosclerosis 2010, 209:35-38.
115. Starr J.M., Shiels P.G., Harris S.E., Pattie A., Pearce M.S., Relton C.L., et al. Oxidative stress, telomere length and biomarkers of physical aging in a cohort aged 79years from the 1932 Scottish Mental Survey. Mech. Ageing Dev. 2008, 129:745-751.
116. Salpea K.D., Talmud P.J., Cooper J.A., Maubaret C.G., Stephens J.W., Abelak K., et al. Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis 2010, 209:42-50.
117. Jennings P., Koppelstaetter C., Aydin S., Abberger T., Wolf A.M., Mayer G., et al. Cyclosporine A induces senescence in renal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 2007, 293:F831-F838.
118. Choi J., Fauce S.R., Effros R.B. Reduced telomerase activity in human T lymphocytes exposed to cortisol. Brain Behav. Immun. 2008, 22:600-605.
119. Qi H., Chen Y., Fu X., Lin C.P., Zheng X.F., Liu L.F. TOR regulates cell death induced by telomere dysfunction in budding yeast. PLoS One 2008, 3:e3520.
120. Sloand E.M., Pfannes L., Ling C., Feng X., Jasek M., Calado R., et al. Graft-versus-host disease: role of inflammation in the development of chromosomal abnormalities of keratinocytes. Biol. Blood Marrow Transplant. 2010, 16:1665-1673.
121. Martin-Pena A., Aguilar-Guisado M., Espigado I., Parody R., Miguel C.J. Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. Clin. Transplant. 2010.
122. Kitay-Cohen Y., Goldberg-Bittman L., Hadary R., Fejgin M.D., Amiel A. Telomere length in hepatitis C. Cancer Genet. Cytogenet. 2008, 187:34-38.
123. van de Berg P.J., Griffiths S.J., Yong S.L., Macaulay R., Bemelman F.J., Jackson S., et al. Cytomegalovirus infection reduces telomere length of the circulating T cell pool. J. Immunol. 2010, 184:3417-3423.
124. Martin-Pena A., Aguilar-Guisado M., Espigado I., Parody R., Miguel C.J. Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. Clin. Transplant. 2010.
125. Fukunaga A., Ishikawa T., Kishihata M., Shindo T., Hori T., Uchiyama T. Altered homeostasis of CD4(+) memory T cells in allogeneic hematopoietic stem cell transplant recipients: chronic graft-versus-host disease enhances T cell differentiation and exhausts central memory T cell pool. Biol. Blood Marrow Transplant. 2007, 13:1176-1184.
126. Herrera E., Martinez A., Blasco M.A. Impaired germinal center reaction in mice with short telomeres. EMBO J. 2000, 19:472-481.
127. Ilmonen P., Kotrschal A., Penn D.J. Telomere attrition due to infection. PLoS One 2008, 3:e2143.
128. Cassidy A., De V.I., Liu Y., Han J., Prescott J., Hunter D.J., et al. Associations between diet, lifestyle factors, and telomere length in women. Am. J. Clin. Nutr. 2010, 91:1273-1280.
129. Cherkas L.F., Hunkin J.L., Kato B.S., Richards J.B., Gardner J.P., Surdulescu G.L., et al. The association between physical activity in leisure time and leukocyte telomere length. Arch. Intern. Med. 2008, 168:154-158.
130. Valdes A.M., Andrew T., Gardner J.P., Kimura M., Oelsner E., Cherkas L.F., et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005, 366:662-664.
131. Mirabello L., Huang W.Y., Wong J.Y., Chatterjee N., Reding D., Crawford E.D., et al. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell 2009, 8:405-413.
132. Morla M., Busquets X., Pons J., Sauleda J., MacNee W., Agusti A.G. Telomere shortening in smokers with and without COPD. Eur. Respir. J. 2006, 27:525-528.
133. McGrath M., Wong J.Y., Michaud D., Hunter D.J., De V. I. Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol. Biomarkers Prev. 2007, 16:815-819.
134. Lee D.C., Im J.A., Kim J.H., Lee H.R., Shim J.Y. Effect of long-term hormone therapy on telomere length in postmenopausal women. Yonsei Med. J. 2005, 46:471-479.
135. Epel E.S., Blackburn E.H., Lin J., Dhabhar F.S., Adler N.E., Morrow J.D., et al. Accelerated telomere shortening in response to life stress. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:17312-17315.
136. Packman W., Weber S., Wallace J., Bugescu N. Psychological effects of hematopoietic SCT on pediatric patients, siblings and parents: a review. Bone Marrow Transplant. 2010, 45:1134-1146.
137. Simon N.M., Smoller J.W., McNamara K.L., Maser R.S., Zalta A.K., Pollack M.H., et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol. Psychiatry 2006, 60:432-435.
138. Drury S.S., Theall K., Gleason M.M., Smyke A.T., De V.I., Wong J.Y., et al. Telomere length and early severe social deprivation: linking early adversity and cellular aging. Mol. Psychiatry 2011.
139. Jacobs T.L., Epel E.S., Lin J., Blackburn E.H., Wolkowitz O.M., Bridwell D.A., et al. Intensive meditation training, immune cell telomerase activity, and psychological mediators. Psychoneuroendocrinology 2011, 36:664-681.
140. Diaz V.A., Mainous A.G., Everett C.J., Schoepf U.J., Codd V., Samani N.J. Effect of healthy lifestyle behaviors on the association between leukocyte telomere length and coronary artery calcium. Am. J. Cardiol. 2010, 106:659-663.
141. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
142. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
143. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146.
144. Dravid G.G., Crooks G.M. The challenges and promises of blood engineered from human pluripotent stem cells. Adv. Drug Deliv. Rev. 2011.
145. Marion R.M., Strati K., Li H., Tejera A., Schoeftner S., Ortega S., et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell 2009, 4:141-154.
146. Batista L.F., Pech M.F., Zhong F.L., Nguyen H.N., Xie K.T., Zaug A.J., et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 2011.
147. Yehezkel S., Rebibo-Sabbah A., Segev Y., Tzukerman M., Shaked R., Huber I., et al. Reprogramming of telomeric regions during the generation of human induced pluripotent stem cells and subsequent differentiation into fibroblast-like derivatives. Epigenetics 2011, 6:63-75.
148. Suhr S.T., Chang E.A., Rodriguez R.M., Wang K., Ross P.J., Beyhan Z., et al. Telomere dynamics in human cells reprogrammed to pluripotency. PLoS One 2009, 4:e8124.
149. Gourronc F.A., Klingelhutz A.J. Therapeutic opportunities: telomere maintenance in inducible pluripotent stem cells. Mutat. Res. 2011.
150. Marion R.M., Blasco M.A. Telomere rejuvenation during nuclear reprogramming. Curr. Opin. Genet. Dev. 2010, 20:190-196.
151. Abou-Mourad Y.R., Lau B.C., Barnett M.J., Forrest D.L., Hogge D.E., Nantel S.H., et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant. 2010, 45:295-302.
152. Willeit P., Willeit J., Mayr A., Weger S., Oberhollenzer F., Brandstatter A., et al. Telomere length and risk of incident cancer and cancer mortality. JAMA 2010, 304:69-75.
153. Wu X., Amos C.I., Zhu Y., Zhao H., Grossman B.H., Shay J.W., et al. Telomere dysfunction: a potential cancer predisposition factor. J. Natl. Cancer Inst. 2003, 95:1211-1218.
154. Shen J., Terry M.B., Gurvich I., Liao Y., Senie R.T., Santella R.M. Short telomere length and breast cancer risk: a study in sister sets. Cancer Res. 2007, 67:5538-5544.
155. Wentzensen I.M., Mirabello L., Pfeiffer R.M., Savage S.A. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2011.
156. Rizzo J.D., Curtis R.E., Socie G., Sobocinski K.A., Gilbert E., Landgren O., et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1175-1183.
157. Curtis R.E., Metayer C., Rizzo J.D., Socie G., Sobocinski K.A., Flowers M.E., et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005, 105:3802-3811.